CY1111522T1 - 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο - Google Patents

84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο

Info

Publication number
CY1111522T1
CY1111522T1 CY20111100538T CY111100538T CY1111522T1 CY 1111522 T1 CY1111522 T1 CY 1111522T1 CY 20111100538 T CY20111100538 T CY 20111100538T CY 111100538 T CY111100538 T CY 111100538T CY 1111522 T1 CY1111522 T1 CY 1111522T1
Authority
CY
Cyprus
Prior art keywords
specific
protein
expressived
protector
cancer
Prior art date
Application number
CY20111100538T
Other languages
English (en)
Inventor
Aya Jakobovits
Daniel E H Afar
Pia M Challita-Eid
Elana Levin
Steve Chappell Mitchell
Rene S Hubert
Original Assignee
Agensys, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys, Inc. filed Critical Agensys, Inc.
Publication of CY1111522T1 publication Critical patent/CY1111522T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Περιγράφεται νέο γονίδιο (που ορίζεται 84Ρ2Α9) και η κωδικοποιούμενη πρωτεΐνη του. Ενώ το 84Ρ2Α9 επιδεικνύει ειδική σε προστάτη και όρχεις έκφραση σε κανονικό ιστό ενήλικα, εκφράζεται κατά παρεκτροπή σε πολλούς καρκίνους που περιλαμβάνουν καρκίνους προστάτη, όρχεων, νεφρού, εγκεφάλου, οστού, δέρματος, ωοθήκης, μαστού, παγκρέατος, κόλου, λεμφοκυτταρικούς και πνευμονικούς καρκίνους. Συνεπώς, το 84Ρ2Α9 παρέχει διαγνωστικό ή/και θεραπευτικό στόχο για καρκίνους, και το 84Ρ2Α9 γονίδιο ή θραύσμα αυτού, ή η κωδικοποιούμενη πρωτεΐνη του ή θραύσμα αυτής που χρησιμοποιούνται για να προκληθεί ανοσοαπόκριση.
CY20111100538T 2000-01-26 2011-06-03 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο CY1111522T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17856000P 2000-01-26 2000-01-26
EP08154530A EP1967586B1 (en) 2000-01-26 2001-01-26 84P2A9: A prostate and testis specific protein highly expressed in prostate cancer

Publications (1)

Publication Number Publication Date
CY1111522T1 true CY1111522T1 (el) 2015-08-05

Family

ID=22653018

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100538T CY1111522T1 (el) 2000-01-26 2011-06-03 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο

Country Status (12)

Country Link
US (3) US7510855B2 (el)
EP (2) EP1967586B1 (el)
JP (2) JP3946044B2 (el)
AT (2) ATE501255T1 (el)
AU (2) AU2001237973B2 (el)
CA (1) CA2398064C (el)
CY (1) CY1111522T1 (el)
DE (2) DE60144204D1 (el)
DK (1) DK1967586T3 (el)
ES (2) ES2360155T3 (el)
IL (2) IL150873A0 (el)
WO (1) WO2001055391A2 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1967586T3 (da) 2000-01-26 2011-06-20 Agensys Inc 84P2A9: prostata- og testikelspecifikt protein med høj ekspression ved prostatacancer
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK1994155T4 (da) 2006-02-13 2022-07-25 Daiichi Sankyo Co Ltd Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering
WO2014012165A1 (en) 2012-07-19 2014-01-23 Alethia Biotherapeutics Inc. Anti-siglec-15 antibodies
US20150231199A1 (en) * 2012-09-07 2015-08-20 Agency For Science, Technology And Research Peptides and their uses

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
TR199902053T2 (xx) * 1997-02-25 2000-04-21 Corixa Corporation Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
WO1998045435A2 (en) 1997-04-10 1998-10-15 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
EP1053319A2 (en) 1998-01-28 2000-11-22 Chiron Corporation Human genes and gene expression products ii
US6013450A (en) 1998-02-20 2000-01-11 Incyte Pharmaceuticals, Inc. CAF1-related protein
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
AU2001229340A1 (en) 2000-01-14 2001-07-24 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
DK1967586T3 (da) * 2000-01-26 2011-06-20 Agensys Inc 84P2A9: prostata- og testikelspecifikt protein med høj ekspression ved prostatacancer
WO2001055447A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2001077289A2 (en) 2000-04-06 2001-10-18 Genetics Institute, Llc. Polynucleotides encoding novel secreted proteins
CN1328147A (zh) 2000-06-12 2001-12-26 上海博德基因开发有限公司 一种新的多肽——人磷脂酶49.06和编码这种多肽的多核苷酸
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
WO2002010449A2 (en) 2000-07-28 2002-02-07 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
CA2421949A1 (en) 2000-09-11 2002-03-21 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001296235A1 (en) 2000-10-12 2002-04-22 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2002253878A1 (en) 2001-01-25 2002-08-06 Gene Logic, Inc. Gene expression profiles in breast tissue

Also Published As

Publication number Publication date
DE60133627D1 (de) 2008-05-29
JP2003520605A (ja) 2003-07-08
ES2360155T3 (es) 2011-06-01
AU2001237973B2 (en) 2006-09-07
US7510855B2 (en) 2009-03-31
CA2398064C (en) 2012-12-18
ATE392474T1 (de) 2008-05-15
US7582448B2 (en) 2009-09-01
WO2001055391A2 (en) 2001-08-02
AU3797301A (en) 2001-08-07
EP1250434A2 (en) 2002-10-23
ES2304126T3 (es) 2008-09-16
US20070054363A1 (en) 2007-03-08
EP1250434B1 (en) 2008-04-16
DE60133627T2 (de) 2009-07-30
DE60144204D1 (de) 2011-04-21
CA2398064A1 (en) 2001-08-02
IL150873A0 (en) 2003-02-12
EP1967586A1 (en) 2008-09-10
IL150873A (en) 2010-02-17
JP3946044B2 (ja) 2007-07-18
US8013126B2 (en) 2011-09-06
ATE501255T1 (de) 2011-03-15
EP1967586B1 (en) 2011-03-09
JP2006325595A (ja) 2006-12-07
DK1967586T3 (da) 2011-06-20
US20090170191A1 (en) 2009-07-02
JP5501550B2 (ja) 2014-05-21
WO2001055391A3 (en) 2002-02-21
US20040126862A1 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
CY1111147T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
MXPA03001634A (es) Polipeptido tumoral cripto.
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
DE60332355D1 (de) Hla-a24-restringiertes krebsantigenpeptid
DE69231734D1 (de) Geerbte und somatische mutationen des apc-gens bei menschlichem colorectal-krebs
CY1111522T1 (el) 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
TR200001646T2 (tr) Bir salgılanmış meme kanseri proteini olan mamaglobin.
BR0010702A (pt) Novas quinonas como terapias de doenças
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
BR9808509A (pt) Composições e métodos para o tratamento e diagnóstico do câncer de mama
ATE426617T1 (de) Therapeutische und diagnostische anti-hsp 70- antikírper
HUP0300054A1 (hu) Daganatspecifikus állati fehérjék
AU3392901A (en) Proteins
IL207012A (en) 28sgp medicinal product and 28sgp accent cancer treatment vaccine
CY1109029T1 (el) Νουκλεϊνικο οξυ και αντιστοιχη πρωτεϊνη ονομαζομενη 85p1b3 χρησιμα στην αγωγη και τον εντοπισμο του καρκινου
MXPA02011563A (es) Composicionesy metodos para la terapia y diagnostico de cancer de seno.
ES2174103T3 (es) Uso de las secuencias reguladoras de wap o mmtv para expresion dirigida de genes heterologos ligados en celulas mamarias humanas, con inclusion de celulas de carcinoma mamario humano.
AU2002251754A1 (en) Therapeutic modulation of the tumor inflammatory response
HUP0300923A2 (hu) RAF és RAS protein kinázt tartalmazó készítmények és alkalmazásuk angiogenezis módosítására
ATE373711T1 (de) Gewebe-spezifische protein 103p2d6, hochexprimiert in verschiedene krebsarten
CY1108761T1 (el) Απενεργοποιημενες κυτοκινες για ανοσοποιηση
WO2001059110A3 (en) 34p3d7: a tissue specific protein highly expressed in prostate cancer
ATE527282T1 (de) Tumor assoziierte antigene